[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exercise-capacity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exercise-capacity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,74,98,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100357965","fatigue-and-skeletal-muscle-impact-in-severe-axial-spondyloarthritis-100357965",false,"NCT03940911","Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis","Famuspa","Inclusion criteria:\n\n* Axial SA according to the ASAS criteria;\n* Targeted therapy naïve patients\n* Indication to start a targeted therapy;\n* Initiation of targeted therapy ≤ 15 days before inclusion\n* ≥ 18 years old, no upper age limit;\n* Subject affiliated to a social health insurance reimbursement;\n* Subject able to understand the aims and risks of the research and having signed a dated and informed consent\n* Subject informed of the results of the preliminary medical examination\n* Woman in childbearing age: negative beta-HCG test and effective contraception;\n* Sufficient understanding of French to follow the protocol.\n\nExclusion criteria:\n\n* Targeted therapy in progress for \\> 15 days prior to inclusion\n* Contraindication to the use of targeted therapy\n* Systemic corticosteroids in the 15 days preceding the V0 visit\n* Associated extramuscular inflammatory disease (s) (excluding ocular and cutaneous involvement) eg chronic inflammatory bowel disease\n* Associated fibromyalgia (Questionnaire score FiRST ≥5) achieved during the V0 visit\n* History of coronary artery disease: exercise angina, acute coronary syndrome and \u002F or coronary angioplasty,\n* History of lower extremity arterial disease: vascular claudication and \u002F or lower extremity angioplasty\n* COPD\n* Neuromuscular pathology\n* Insufficiency of organ (renal, hepatic pulmonary heart)\n* Sleep apnea\n* Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject, etc.)\n* Subject under the protection of justice\n* Subject under guardianship or curatorship\n* Breastfeeding\n* Pregnancy\n* Subject in exclusion period defined by another clinical study or participating in a study likely to impact the results of the research","ALL","18 Years",{"count":19,"type":20},122,"ESTIMATED","INTERVENTIONAL",[23],"NA","Axial spondyloarthropathy (SpA) is the most common inflammatory rheumatism (1% of the general population) with important medico-economic consequences.\n\nFatigue is a major feature of SA. It can be defined as a feeling of reduced muscle capacity, lack of energy and exhaustion. The fatigue reaches an abnormally high level (fatigue severity score (FSS) ≥4, called severe fatigue in this protocol) in more than two thirds of patients with SA.\n\nSkeletal muscle repercussions are present during SA. It is characterized by a decrease in exercise capacity independently of pain and ankylosis but is associated with a decrease in strength and muscle mass, the importance of which varies from one study to another.\n\nThe link between fatigue (subjective sensation) and the skeletal muscular impact (objective) of SA has never been studied.",[26,27,28],"Spondyloarthritis, Axial","Fatigue","Exercise Capacity",[30,27,31,32,33],"Axial spondylarthritis","Targeted therapy","Exercise capacity","Sarcopenia","RECRUITING","2026-03-09",{"date":37,"type":38},"2026-03-12","ACTUAL",{"date":40,"type":38},"2025-11-13",{"date":42,"type":20},"2029-12",{"name":44,"class":45},"University Hospital, Strasbourg, France","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100589015","validity-and-reliability-of-6-minute-pegboard-and-ring-test-in-patients-with-interstitial-lung-disease-100589015","NCT06948916","Validity and Reliability of 6-minute Pegboard and Ring Test in Patients With Interstitial Lung Disease","Investigation of the Validity and Reliability of 6-minute Pegboard and Ring Test in Patients With Interstitial Lung Disease","Inclusion Criteria:\n\n* Patients diagnosed with ILD according to ATS\u002FERS criteria,\n* Ages between 18 and 75,\n* Pulmonary infection during the previous month,\n* Participants who voluntarily participated in the study were included.\n\nExclusion Criteria:\n\n* Patients were excluded if they had:\n* Acute pulmonary exacerbation or respiratory infection in the last four weeks\n* Obstructive lung disease\n* Systemic conditions affecting neurological, neuromuscular, orthopedic, or physical functions\n* Recent participation in a planned exercise program (within three months)\n* Cognitive impairment affecting exercise test understanding\n* Contraindications to exercise testing per the American Sports Medicine Association\n* Cancer, renal, or hepatic disease\n* Aortic stenosis, complex arrhythmia, or aortic aneurysm\n* Serious cardiovascular diseases like uncontrolled hypertension, diabetes, heart failure, or arrhythmia","75 Years",{"count":56,"type":20},34,"OBSERVATIONAL","Interstitial lung diseases (ILD) are a heterogeneous group of chronic respiratory diseases that cause significant mortality and morbidity worldwide, characterized by diffuse inflammation in the lung parenchyma and vascular structures, can progress to fibrosis, have known or unknown etiology, and can develop secondary to systemic autoimmune connective tissue diseases other than diseases where the primary pathology is in the lung. The 6-minute peg-board and ring test, which was first developed to determine the upper extremity exercise capacity of chronic obstructive pulmonary disease patients, is an exercise test used to evaluate upper extremity functional exercise capacity in different lung diseases. It has been determined that there is no study on the validity and reliability of this test in individuals with ILD.",[60,28,61],"Interstitial Lung Diseases (ILD)","Upper Extremity",[63,28,64],"Interstitial lung diseases","Upper extremity","2025-04-22",{"date":67,"type":38},"2025-04-29",{"date":69,"type":38},"2024-12-12",{"date":71,"type":20},"2025-08-12",{"name":73,"class":45},"Gazi University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100589017","exercise-capacity-muscle-oxygenation-and-physical-activity-between-patients-with-interstitial-lung-disease-100589017","NCT06948942","Exercise Capacity, Muscle Oxygenation, and Physical Activity Between Patients With Interstitial Lung Disease","Comparison of Exercise Capacity, Muscle Oxygenation and Physical Activity Levels Between Patients With Interstitial Lung Disease and Healthy Individuals","Patients who will participate in the study;\n\nInclusion Criteria:\n\n* Patients diagnosed with ILD according to ATS\u002FERS criteria,\n* Ages between 18 and 75,\n* Pulmonary infection during the previous month,\n* Participants who voluntarily participated in the study were included.\n\nExclusion Criteria:\n\n* Patients were excluded if they had:\n* Acute pulmonary exacerbation or respiratory infection in the last four weeks\n* Obstructive lung disease\n* Systemic conditions affecting neurological, neuromuscular, orthopedic, or physical functions\n* Recent participation in a planned exercise program (within three months)\n* Cognitive impairment affecting exercise test understanding\n* Contraindications to exercise testing per the American Sports Medicine Association\n* Cancer, renal, or hepatic disease\n* Aortic stenosis, complex arrhythmia, or aortic aneurysm\n* Serious cardiovascular diseases like uncontrolled hypertension, diabetes, heart failure, or arrhythmia\n\nFor healthy individuals who will participate in the study;\n\nInclusion Criteria:\n\n* No diagnosed chronic disease,\n* Healthy adults between the ages of 45-80\n\nExclusion Criteria:\n\n* Individuals with a Mini Mental State Assessment Scale score of less than 24,\n* A smoking history of at least 10 packs×years or more,\n* Having had COVID-19,\n* A BMI of \\>30 kg\u002Fm2",true,{"count":83,"type":20},40,"Interstitial lung diseases (ILD) are a group of chronic respiratory diseases that cause significant mortality and morbidity worldwide. Although there are studies in the literature comparing different lung disease groups with healthy individuals, it has been determined that there is no study comparing the exercise capacity, muscle oxygenation, physical activity level, respiratory functions, respiratory and peripheral muscle strength, inspiratory muscle endurance, quality of life and sleep quality of individuals diagnosed with ILD with healthy individuals.",[60,86,28,87,88],"Healthy Individuals","Muscle Oxygenation","Physical Activity Level",[63,90,32,91,92],"Healthy individuals","Muscle oxygenation","Physical activity level",{"date":67,"type":38},{"date":69,"type":38},{"date":96,"type":20},"2025-09-12",{"name":73,"class":45},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":46},"100409419","lung-function-exercise-capacity-and-serology-responses-in-patients-with-covid-19-100409419","NCT04611243","Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","Inclusion Criteria: Patients who have been discharged from hospital following treatment for COVID-19 -\n\nExclusion Criteria: Unwilling to be follow up\n\n\\-",{"count":105,"type":20},700,"(a) Objectives\n\n1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years.\n2. To assess the longevity of the serology response to SARS-CoV2.\n3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model\n4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines.\n5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)",[108,28,109,110],"Lung Function","Quality of Life","Covid19","2024-08-19",{"date":113,"type":38},"2024-08-21",{"date":115,"type":38},"2020-05-22",{"date":117,"type":20},"2026-02-17",{"name":119,"class":45},"Chinese University of Hong Kong",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":81,"sex":16,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":46},"100253249","exercise-capacity-in-diseases-and-health-100253249","NCT02575469","Exercise Capacity in Diseases and Health","Inclusion Criteria:\n\n* Ability to complete full exercise evaluation (including cardiopulmonary exercise testing).\n\nExclusion Criteria:\n\n* Acute illness on visit day.\n* for healthy volunteers: chronic disease or use of medications.\n* Professional athletes.","6 Years","90 Years",{"count":129,"type":20},500,"Exercise capacity is a key factor to evaluate and treat patients in different diseases (e.g. ischemic heart disease, chronic obstructive pulmonary disease, cystic fibrosis). The best way to measure exercise capacity is to perform a cardiopulmonary exercise testing. Normal\u002Freference values in health and disease relate to specific population and subpopulations. The population in Israel is unique in its diversity.\n\nObjectives: Data collection of exercise capacity assessment in health and illness in the northern of Israel for future local database.\n\nPopulation: 500 Patients evaluated routinely in the exercise lab (pediatric cardiology institute) and healthy volunteers evaluated as controls.\n\nStudy design: Prospective observational study. Participants will answer a health related questioner, undergo a physical examination, perform a cardiopulmonary exercise test on a treadmill or a cycle ergometer.",[28],"NOT_YET_RECRUITING","2017-01-23",{"date":135,"type":20},"2017-01-24",{"date":137,"type":20},"2017-10-01",{"date":139,"type":20},"2036-01-01",{"name":141,"class":45},"Rambam Health Care Campus"]